Excellent! Worth noting that whilst only 3/11 patients show a 50% or greater reduction at the midpoint, this is a dose escalation trial so the midpoint is determined as being a dose of 90mg, with the dosage then increasing to 150mg and then finally 240mg.
One patient who had completed the study had a 66% reduction in proteinuria at only a 90mg dose!
Lets see what the market thinks here today and overnight as I bet a few Retrophin investors are keeping an eye out here.
- Forums
- ASX - By Stock
- DXB
- Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-4
-
-
- There are more pages in this discussion • 217 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
55.0¢ |
Change
-0.060(9.84%) |
Mkt cap ! $302.3M |
Open | High | Low | Value | Volume |
60.5¢ | 61.0¢ | 55.0¢ | $2.309M | 4.010M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 137019 | 55.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
55.5¢ | 22500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 130691 | 0.550 |
4 | 35536 | 0.545 |
8 | 158059 | 0.540 |
3 | 46869 | 0.535 |
6 | 173766 | 0.530 |
Price($) | Vol. | No. |
---|---|---|
0.555 | 22500 | 1 |
0.560 | 21428 | 1 |
0.565 | 45284 | 3 |
0.575 | 10268 | 1 |
0.585 | 41022 | 3 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online